Unfortunately, this strategy failed to show clinical benefit in the overall breast cancer patient population44 as demonstrated by no improvement in disease-free survival when the IGF-IR antibody ganitumab was added to endocrine treatment.33 Considering the lack of benefit in this phase III trials, several drug sponsors terminated their IGF-1R drug development programs37 in recent years. The gene discussed is IGF1R; the disease is breast carcinoma.